Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma

Trial Profile

Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Leukaemia; Lymphoma; Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results of two completed phase II trials (NCT00436618 and NCT00918333) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 15 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top